Biomarkers for ovarian cancer
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry.
1. A method for qualifying ovarian cancer status in a subject comprising:
(a) measuring Calcyclin, Calgranulin C and Hepcidin in an ovarian cyst fluid, urine, or serum sample from the subject by mass spectrometry or immunoassay to determine the presence, absence, or level of the measured Calcyclin, Calgranulin C and Hepcidin biomarkers, and
(b) correlating the measurements of the presence, absence, or level of the measured Calcyclin, Calgranulin C and Hepcidin biomarkers with ovarian cancer status.
2. The method of claim 1 , further comprising measuring and correlating at least one biomarker selected from the group consisting of: ApoC1, ApoAII, ApoCII, Calgranulin A, and Transthyretin.
3. The method of claim 1 further comprising measuring CA125.
4. The method of claim 1 , wherein the Calcyclin, Calgranulin C, and Hepcidin are measured by capture on an adsorbent surface of a SELDI probe and detection by laser desorption-ionization mass spectrometry.
5. The method of claim 4 , wherein the adsorbent is a member selected from the group consisting of a hydrophobic adsorbent, an anion exchange adsorbent, a cation exchange adsorbent and a metal chelate adsorbent.
6. The method of claim 4 , wherein the adsorbent is a cation exchange adsorbent.
7. The method of claim 1 , wherein Calcyclin and Hepcidin are measured by immunoassay.
8. The method of claim 1 , wherein the sample is ovarian cyst fluid.
9. The method of claim 1 , wherein the correlating is performed by a software classification algorithm.
10. The method of claim 1 , wherein ovarian cancer status is selected from benign ovarian disease, ovarian cancer of low malignant potential, ovarian cancer and other malignant conditions.
11. The method of claim 1 , wherein the presence of calcyclin rules out benign ovarian disease.
12. The method of claim 1 , wherein the presence of calgranulin C rules out benign ovarian disease.
13. The method of claim 1 , wherein the ovarian cancer status rules out the possibility of benign ovarian disease.
14. The method of claim 1 , wherein the ovarian cancer status rules out the possibility of ovarian cancer and other malignant conditions.
15. The method of claim 1 , further comprising: (c) managing subject treatment based on the status.
16. The method of claim 15 , wherein, if the measurement correlates with ovarian cancer, then managing subject treatment comprises administering a chemotherapeutic agent to the subject.
17. The method of claim 15 , further comprising: (d) measuring Calcyclin, Calgranulin C, and Hepcidin after subject management and correlating the measurement with disease progression.
18. The method of claim 1 , further comprising: (c) reporting the status to the subject.
19. The method of claim 1 , further comprising: (c) recording the status on a tangible medium.